Fulgent Genetics, Inc.
FLGT
Positions held
Your positionsFLGT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $572.87M | Enterprise value | $319.81M | Trailing P/E | — | Forward P/E | -15.09 |
| PEG | — | Price / book | 0.57 | Beta | 0.93 | Dividend yield | 0.00% |
| Revenue growth | 4.4% | Earnings growth | — | Gross margin | 35.6% | Operating margin | -39.4% |
| Profit margin | -26.0% | ROE | -8.1% | ROA | -6.3% | Debt / equity | 0.01 |
| Current ratio | 6.34 | Free cash flow | -$90.90M | Analyst recommendation | none | Mean target | $19.00 |
| 52w high | $31.04 | 52w low | $13.46 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $85.4M | $71.1M | $83.3M | $84.1M | $81.8M |
| Op margin | -39.7% | -48.7% | -43.5% | -18.3% | -24.1% |
| Net income | -$29.5M | -$24.8M | -$23.4M | -$6.6M | -$19.0M |
| Gross margin | 30.1% | 30.2% | 39.1% | 42.2% | 42.1% |
| Gross profit | $25.7M | $21.5M | $32.6M | $35.5M | $34.4M |
| Operating income | -$33.9M | -$34.6M | -$36.2M | -$15.3M | -$19.7M |
- Revenue +20% vs prior quarter ($85M vs $71M).
- Gross margin 30.1% (was 30.2% prior quarter).
- Operating margin expanded to -39.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $323M | $283M | $289M | $619M | — |
| Op margin | -28.2% | -26.1% | -26.0% | 29.3% | — |
| Net income | -$60.5M | -$42.7M | -$168M | $143M | — |
| Gross margin | 40.6% | 37.8% | 36.1% | 59.3% | — |
| Gross profit | $131M | $107M | $104M | $367M | — |
| Operating income | -$91.1M | -$73.9M | -$75.3M | $182M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-22 · PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
2026-08-08 · Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
2026-08-06 · Fulgent Genetics (FLGT) Stock Gets Fair Value Boost After Analysts Raised Targets
2026-07-31 · Fulgent Genetics, Inc. Q2 2026 Earnings Call Summary
2026-07-31 · Fulgent Genetics Inc (FLGT) (Q2 2026) Earnings Call Highlights: Strategic Progress Amid Revenue ...
2026-07-30 · Fulgent Genetics Q2 Earnings Call Highlights
2026-07-30 · Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
2026-07-30 · Fulgent Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns